A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
Alimentary Pharmacology & Therapeutics2014Vol. 39(10), pp. 1126–1135
Citations Over TimeTop 1% of 2014 papers
Barrett G. Levesque, Gordon R. Greenberg, Guangyong Zou, William J. Sandborn, Sharat Singh, Scott Hauenstein, Linda Ohrmund, Cindy J. Wong, Larry Stitt, Lisa M. Shackelton, Debra King, S. Lockton, James Ducharme, Brian G. Feagan
Abstract
This prospective study confirms the relationship between trough infliximab concentrations, inflammation and antibodies-to-infliximab. Infliximab trough concentrations below 3 μg/mL may increase the likelihood of symptoms and inflammation (ClinicalTrials.gov identifier: NCT00676988).
Related Papers
- → Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases(2011)158 cited
- → Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease(2011)111 cited
- Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.(2006)
- → Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study(2011)41 cited
- [Management of failure of infliximab in inflammatory bowel disease].(2011)